"description","studyEstimands","name","studyDesignRationale","label","documentVersion","uuid:ID","bcCategories","studyInvestigationalInterventions","id"
"The main design for the study","[]","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","","67b0e1d4-cc09-4cb3-822d-bc92f26129b6","[]","[]","StudyDesign_1"
